Chemours Co (CC)
Official siteBASIC MATERIALS • SPECIALTY CHEMICALS • NYSE
Market Cap: $2.00B
Last updated: Nov 17, 2026 at 11:04 AM ET
Chemours Co (CC) Earnings: Report Dates and Results
Chemours (CC) is expected to report earnings on Feb 17, 2027. In the quarter ended Sep 30, 2026, Chemours reported EPS of $0.21, below the $0.26 estimate. It beat the EPS estimate in 2 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
CC has an expected report date of Feb 17, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 180.0% above the $0.05 reported for the quarter ended Dec 31, 2025.
CC Earnings Call
The latest CC earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, CC beat 27 and missed 13. Revenue for the quarter ended Sep 30, 2026 was $1.54B, up 2.7% from $1.50B a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.21 | $0.26 | $0.17 - $0.39 | -19.23% | Miss | +5.0% | 9 | 0 up, 3 down | Nov 2, 2026 | $1.54B |
| Jun 30, 2026 | $0.42 | $0.43 | -$0.19 - $0.56 | -2.33% | Miss | -27.6% | 9 | 3 up, 0 down | Aug 4, 2026 | $1.59B |
| Mar 31, 2026 | $0.05 | $0.20 | N/A | -75.44% | Miss | -61.5% | 8 | 3 up, 0 down | May 5, 2026 | $1.38B |
| Dec 31, 2025 | $0.05 | $0.02 | -$0.06 - $0.15 | +150.00% | Beat | -54.5% | 8 | 1 up, 1 down | Feb 19, 2026 | $1.33B |
| Sep 30, 2025 | $0.20 | $0.24 | $0.20 - $0.29 | -16.67% | Miss | -50.0% | 9 | 2 up, 1 down | Nov 6, 2025 | $1.50B |
| Jun 30, 2025 | $0.58 | $0.46 | $0.38 - $0.53 | +26.09% | Beat | +52.6% | 9 | 0 up, 6 down | Aug 5, 2025 | $1.61B |
| Mar 31, 2025 | $0.13 | $0.20 | $0.14 - $0.36 | -35.00% | Miss | -59.4% | 9 | 1 up, 5 down | May 6, 2025 | $1.37B |
| Dec 31, 2024 | $0.11 | $0.16 | $0.04 - $0.40 | -31.25% | Miss | -64.5% | 10 | 0 up, 3 down | Feb 18, 2025 | $1.36B |
| Sep 30, 2024 | $0.40 | $0.28 | $0.23 - $0.34 | +42.86% | Beat | -36.5% | 9 | 0 up, 0 down | Nov 4, 2024 | $1.51B |
| Jun 30, 2024 | $0.38 | $0.58 | $0.34 - $1.10 | -34.48% | Miss | -65.5% | 9 | 0 up, 0 down | Aug 1, 2024 | $1.55B |
| Mar 31, 2024 | $0.32 | $0.17 | $0.09 - $0.39 | +88.24% | Beat | -67.3% | 7 | 0 up, 0 down | Apr 30, 2024 | $1.36B |
| Dec 31, 2023 | $0.31 | $0.25 | $0.12 - $0.43 | +24.00% | Beat | N/A | 9 | 1 up, 0 down | Mar 27, 2024 | $1.41B |
| Sep 30, 2023 | $0.63 | $0.69 | $0.48 - $0.87 | -8.70% | Miss | -49.2% | 9 | 0 up, 0 down | Oct 26, 2023 | $1.49B |
| Jun 30, 2023 | $1.10 | $1.07 | $1.00 - $1.21 | +2.80% | Beat | -41.8% | 11 | 0 up, 0 down | Jul 27, 2023 | $1.64B |
| Mar 31, 2023 | $0.98 | $0.51 | $0.37 - $0.56 | +92.16% | Beat | -32.9% | 11 | 0 up, 1 down | Apr 27, 2023 | $1.54B |
| Dec 31, 2022 | -$0.65 | $0.10 | -$0.10 - $0.45 | -746.50% | Miss | -179.8% | 11 | 0 up, 0 down | Feb 9, 2023 | $1.38B |
| Sep 30, 2022 | $1.24 | $1.04 | $0.89 - $1.42 | +19.23% | Beat | -2.4% | 11 | 0 up, 0 down | Oct 25, 2022 | $1.78B |
| Jun 30, 2022 | $1.89 | $1.42 | $1.34 - $1.55 | +33.10% | Beat | +57.5% | 11 | 1 up, 0 down | Jul 28, 2022 | $1.92B |
| Mar 31, 2022 | $1.46 | $0.91 | $0.83 - $1.04 | +60.44% | Beat | +105.6% | 9 | 3 up, 0 down | May 2, 2022 | $1.76B |
| Dec 31, 2021 | $0.81 | $0.88 | $0.77 - $0.99 | -7.95% | Miss | +30.6% | 11 | 1 up, 0 down | Feb 10, 2022 | $1.57B |
| Sep 30, 2021 | $1.27 | $1.02 | $0.95 - $1.08 | +24.51% | Beat | +170.2% | 11 | N/A | Nov 4, 2021 | $1.68B |
| Jun 30, 2021 | $1.20 | $0.94 | $0.66 - $1.08 | +27.66% | Beat | +566.7% | 11 | N/A | Jul 29, 2021 | $1.66B |
| Mar 31, 2021 | $0.71 | $0.64 | $0.49 - $0.78 | +10.94% | Beat | 0.0% | 9 | N/A | May 3, 2021 | $1.44B |
| Dec 31, 2020 | $0.62 | $0.41 | $0.24 - $0.53 | +51.22% | Beat | +10.7% | 9 | N/A | Feb 11, 2021 | $1.34B |
| Sep 30, 2020 | $0.47 | $0.33 | $0.30 - $0.35 | +42.42% | Beat | -20.3% | 9 | N/A | Nov 3, 2020 | $1.23B |
| Jun 30, 2020 | $0.18 | $0.11 | -$0.04 - $0.21 | +63.64% | Beat | -75.0% | 11 | N/A | Jul 30, 2020 | $1.09B |
| Mar 31, 2020 | $0.71 | $0.49 | $0.37 - $0.60 | +44.90% | Beat | +12.7% | 11 | N/A | May 5, 2020 | $1.30B |
| Dec 31, 2019 | $0.56 | $0.45 | $0.36 - $0.49 | +24.44% | Beat | -46.7% | 11 | N/A | Feb 13, 2020 | $1.35B |
| Sep 30, 2019 | $0.59 | $0.57 | $0.51 - $0.71 | +3.51% | Beat | -60.4% | 11 | N/A | Nov 4, 2019 | $1.39B |
| Jun 30, 2019 | $0.72 | $0.90 | $0.67 - $1.04 | -20.00% | Miss | -57.9% | 12 | N/A | Aug 1, 2019 | $1.41B |
| Mar 31, 2019 | $0.63 | $0.94 | $0.72 - $1.06 | -32.98% | Miss | -55.3% | 11 | N/A | May 2, 2019 | $1.38B |
| Dec 31, 2018 | $1.05 | $1.03 | $0.90 - $1.13 | +1.94% | Beat | -11.8% | 12 | N/A | Feb 14, 2019 | $1.46B |
| Sep 30, 2018 | $1.49 | $1.42 | $1.32 - $1.56 | +4.93% | Beat | +33.0% | 12 | N/A | Nov 1, 2018 | $1.63B |
| Jun 30, 2018 | $1.71 | $1.57 | $1.46 - $1.77 | +8.92% | Beat | +96.6% | 12 | N/A | Aug 2, 2018 | $1.82B |
| Mar 31, 2018 | $1.41 | $1.22 | $1.15 - $1.30 | +15.57% | Beat | +88.0% | 9 | N/A | May 3, 2018 | $1.73B |
| Dec 31, 2017 | $1.19 | $0.97 | $0.82 - $1.10 | +22.68% | Beat | +1387.5% | 8 | N/A | Feb 14, 2018 | $1.57B |
| Sep 30, 2017 | $1.12 | $1.04 | $0.97 - $1.11 | +7.69% | Beat | +83.6% | 7 | N/A | Nov 2, 2017 | $1.58B |
| Jun 30, 2017 | $0.87 | $0.85 | $0.78 - $0.94 | +2.35% | Beat | +222.2% | 7 | N/A | Aug 2, 2017 | $1.59B |
| Mar 31, 2017 | $0.75 | $0.50 | N/A | +50.00% | Beat | +1150.0% | N/A | N/A | May 1, 2017 | $1.44B |
| Dec 31, 2016 | $0.08 | $0.29 | N/A | -72.41% | Miss | -50.0% | N/A | N/A | Feb 15, 2017 | $1.32B |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $0.96, down 20.7% from the year before. It was $1.02 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $0.96 | -20.7% |
| Dec 31, 2024 | $1.21 | -59.9% |
| Dec 31, 2023 | $3.02 | -23.4% |
| Dec 31, 2022 | $3.94 | -1.2% |
| Dec 31, 2021 | $3.99 | +101.5% |
| Dec 31, 2020 | $1.98 | -20.8% |
| Dec 31, 2019 | $2.50 | -55.8% |
| Dec 31, 2018 | $5.66 | +44.0% |
| Dec 31, 2017 | $3.93 | +285.3% |
| Dec 31, 2016 | $1.02 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,900 words across 12 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 5,874 | 12 | |
| 2026Q2 | Jun 30, 2026 | 6,253 | 13 | |
| 2026Q1 | Mar 31, 2026 | 6,214 | 13 | |
| 2025Q4 | Dec 31, 2025 | 5,555 | 12 | |
| 2025Q3 | Sep 30, 2025 | 6,825 | 16 | |
| 2025Q2 | Jun 30, 2025 | 6,522 | 14 | |
| 2025Q1 | Mar 31, 2025 | 8,570 | 14 | |
| 2024Q4 | Dec 31, 2024 | 7,782 | 10 |
2026Q3 Earnings Call
Opening remarks
Brandon Ontjes Vice President, Head of Strategy and Investor Relations Good morning, everybody. Welcome to The Chemours Company's Third Quarter 26 Earnings Conference Call. I am joined today by Denise Dignam, Chemours' President and Chief Executive Officer, and our Senior Vice President and Chief Financial Officer, Shane W. Hostetter. Before we start, I would like to remind you that comments made on this call, as well as in the supplemental information provided on our website, contain forward-looking statements and involve risks and uncertainties as described in Chemours' SEC filings. These forward-looking statements are not guarantees of future performance and are based on certain assumptions and expectations of future events that may not be realized. Actual results may differ, and Chemours undertakes no duty to update any forward-looking statements as a result of future developments or new information. During this call, we will refer to certain non-GAAP financial measures that we believe are useful to investors evaluating the company's performance. A reconciliation of non-GAAP terms and adjustments is included in our press release issued yesterday evening. Additionally, we also posted our earnings presentation on our website yesterday evening. With that, I will turn the call over to Denise Dignam.
Denise Dignam President and Chief Executive Officer Thank you, Brandon, and thank you, everyone, for joining us this morning. On today's call, I will start with highlights from our third-quarter performance before turning it over to Shane to walk through our fourth-quarter outlook and initial perspective on 2027. I will then close with an update on our strategic execution under Pathway to Thrive. Our third-quarter results reflected strong year-over-year performance in Titanium Technologies and Advanced Performance Materials, paired with disciplined commercial and operational execution across the company despite weakening macroeconomic conditions across our key end markets. Net sales were up 3% year over year as expected, driven by continued pricing momentum in TT and growth of 26% in the APM Performance Solutions business. These more than offset the anticipated softness in TSS due to expected weaker demand in the North American stationary AC aftermarket for Opteon blends. Adjusted EBITDA was $200 million, at the high end of our guidance range, with all businesses contributing above expectations. With this update, I also want to highlight the progress that we have made under Pathway to Thrive to derisk our balance sheet, continue our efforts to reduce litigation exposure, and address leverage. On the litigation front, we were able to reach a settlement with the state of North Carolina and 11 local entities to resolve claims of PFAS and other discharges from our Fayetteville work site, as well as those unrelated to our site. In addition, we received final approval of the judicial consent order with the state of New Jersey.
Frequently Asked Questions About CC
When is Chemours's next earnings date?
Chemours's next earnings report is expected for Feb 17, 2027.
Did CC beat earnings estimates last quarter?
No. Chemours reported EPS of $0.21 for the quarter ended Sep 30, 2026, below the $0.26 estimate by 19.23%.
What EPS do analysts expect from CC next quarter?
The consensus EPS estimate for Chemours for the quarter ending Dec 31, 2026 is $0.14 from 14 analysts, with estimates from $0.08 to $0.20.
How often does CC beat earnings estimates?
Chemours beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -0.48%.
CC pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors